聚合物製藥 CDMO 市場規模、佔有率、成長分析，按服務、按供應商、按最終用戶、按地區 - 2025 年至 2032 年行業預測

預計2023年全球大分子藥物CDMO市場規模將達到118.6億美元，並將從2024年的128.8億美元成長到2032年的249.2億美元，預測期內（2025-2032年）的複合年成長率為8.6%。

由於 FDA 對大分子藥物的核准不斷增加、感染疾病激增以及對創新療法的需求不斷成長，大分子合約開發和受託製造廠商(CDMO) 市場正在迅速發展。製藥和生物技術公司對先進技術的投資進一步加速了與 CDMO 的合作，尤其是在 COVID-19 之後，凸顯了生技藥品在開發疫苗和治療方法中的重要性。這次疫情加速了疫苗和單株抗體生產新技術的採用，並凸顯了美國本土合約服務的需求。然而，聚合物開發的複雜性對可負擔性、速度和功效帶來了挑戰。為了穩定這些複雜的治療藥物，封裝和緩衝技術等創新解決方案應運而生，確保在這個競爭激烈的市場中擁有更強大的供應鏈。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

聚合物藥物 CDMO 市場規模（按服務）

• 市場概況
• 契約製造
  • 臨床
  • 商業的
• 合約開發
  • 細胞株開發
  • 製程開發

聚合物藥物 CDMO 市場規模（依供應商）

• 市場概況
• 哺乳類
• 微生物
• 其他

聚合物藥物 CDMO 市場規模（按最終用戶分類）

• 市場概況
• 生技公司
• 執行長
• 其他

聚合物藥物CDMO市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• Lonza Group（Switzerland）
• Thermo Fisher Scientific（United States）
• Catalent（United States）
• WuXi Biologics（China）
• Samsung Biologics（South Korea）
• Siegfried Holding AG（Switzerland）
• AGC Biologics（United States）
• Avid Bioservices（United States）
• Boehringer Ingelheim BioXcellence（Germany）
• Fujifilm Diosynth Biotechnologies（United States）
• Rentschler Biopharma SE（Germany）
• Recipharm AB（Sweden）
• Syngene International（India）
• KBI Biopharma（United States）
• JHL Biotech（Taiwan）
• Emergent BioSolutions（United States）
• Wuxi AppTec（China）
• BioVectra（Canada）
• Abzena（United Kingdom）

結論和建議

Global Large Molecule Drug Substance CDMO Market size was valued at USD 11.86 billion in 2023 and is poised to grow from USD 12.88 billion in 2024 to USD 24.92 billion by 2032, growing at a CAGR of 8.6% during the forecast period (2025-2032).

The market for large molecule drug substance Contract Development and Manufacturing Organizations (CDMOs) is rapidly evolving, driven by increasing FDA approvals for large molecules, a surge in infectious diseases, and heightened demand for innovative therapeutics. Investment from pharmaceutical and biotech firms in advanced technologies has further spurred partnerships with CDMOs, especially post-COVID-19, highlighting the importance of biologics in developing vaccines and treatments. The pandemic accelerated the adoption of new technologies for vaccine and monoclonal antibody production, while emphasizing the necessity for regional, US-based contract services. However, the intricate nature of large molecule development challenges affordability, speed, and effectiveness. Innovative solutions, such as encapsulation and buffering techniques, have emerged to stabilize these complex therapeutic agents, ensuring a stronger supply chain in this competitive market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Large Molecule Drug Substance Cdmo market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Large Molecule Drug Substance CDMO Market Segmental Analysis

Global Large Molecule Drug Substance CDMO Market is segmented by Service, Source, End-user and region. Based on Service, the market is segmented into Contract Manufacturing and Contract Development. Based on Source, the market is segmented into Mammalian, Microbial and Others. Based on End-user, the market is segmented into Biotech Companies, CRO and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Large Molecule Drug Substance CDMO Market

The global market for Large Molecule Drug Substance CDMOs is principally driven by the surge in research and development of biologics and biosimilars, particularly since the pandemic. Companies have significantly invested in the creation of these substances, and currently, approximately fifty percent of prospective therapeutic candidates in the discovery phase encompass biologics, including peptides, proteins, and monoclonal antibodies. This heightened focus on innovative biologics has led to a robust pipeline of new products, spurring further investment from biopharmaceutical firms. Accordingly, these factors collectively fuel the growth of the large molecule drug substance CDMO sector in the global marketplace.

Restraints in the Global Large Molecule Drug Substance CDMO Market

The Global Large Molecule Drug Substance CDMO market faces several restraints, primarily stemming from stringent regulatory requirements and the inherent complexity of analytically characterizing biologics. These large molecules present unique challenges, as comprehensive characterization is essential to assess their stability, purity, and functionality across various applications. Effective structural validation requires integrating multiple low- and high-resolution techniques, which adds to the intricacies. Furthermore, the recombinant synthesis of these large molecules often leads to various post-translational modifications (PTMs), complicating the characterization process. Nevertheless, an increase in research and development investments is driving growth within the large molecule drug substance CDMO market.

Market Trends of the Global Large Molecule Drug Substance CDMO Market

The Global Large Molecule Drug Substance CDMO market is witnessing significant transformation driven by the rapid growth of large molecule biopharmaceuticals and the unique challenges they present in commercial-scale manufacturing. Unlike small molecules, these biologics require distinct batch processes, often influencing production capacities. The rise of targeted therapies, such as antibody-drug conjugates, is enhancing focus in oncology treatments. Smaller firms are prevalent, often lacking the infrastructure for effective scale-up and technology transfer. Consequently, established CDMOs must innovate their operations and invest in advanced technologies to meet the complex demands of tailored therapies, manage high-potency APIs, and navigate stringent regulatory landscapes.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Large Molecule Drug Substance CDMO Market Size by Service & CAGR (2025-2032)

• Market Overview
• Contract Manufacturing
  • Clinical
  • Commercial
• Contract Development
  • Cell Line Development
  • Process Development

Global Large Molecule Drug Substance CDMO Market Size by Source & CAGR (2025-2032)

• Market Overview
• Mammalian
• Microbial
• Others

Global Large Molecule Drug Substance CDMO Market Size by End-user & CAGR (2025-2032)

• Market Overview
• Biotech Companies
• CRO
• Others

Global Large Molecule Drug Substance CDMO Market Size & CAGR (2025-2032)

• North America (Service, Source, End-user)
  • US
  • Canada
• Europe (Service, Source, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Service, Source, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Service, Source, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Service, Source, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Lonza Group (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siegfried Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AGC Biologics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Avid Bioservices (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim BioXcellence (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Diosynth Biotechnologies (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rentschler Biopharma SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recipharm AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syngene International (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KBI Biopharma (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• JHL Biotech (Taiwan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent BioSolutions (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wuxi AppTec (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioVectra (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abzena (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations